Ganymed (CEO Dr. Özlem Türeci) is a biopharmaceutical company located in Mainz, Germany, which focuses on the development of antibodies against cancer. Under the contract, Astellas will pay EUR 422 million to acquire 100% of the equity in Ganymed. In addition, Ganymed’s shareholders will become eligible to receive up to EUR 860 million in further contingent payments based on progress in the development of IMAB362, Ganymed’s most advanced clinical program.

Astellas news release, October 28, 2016